Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon.
作者信息
Park Sang Hyoung
机构信息
Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
出版信息
Crohns Colitis 360. 2023 Aug 26;5(3):otad046. doi: 10.1093/crocol/otad046. eCollection 2023 Jul.
Abstract
摘要
相似文献
1
Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon.
Crohns Colitis 360. 2023 Aug 26;5(3):otad046. doi: 10.1093/crocol/otad046. eCollection 2023 Jul.
2
Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report.
Medicine (Baltimore). 2021 Sep 24;100(38):e27283. doi: 10.1097/MD.0000000000027283.
3
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
4
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
J Clin Pharmacol. 2019 Apr;59(4):590-604. doi: 10.1002/jcph.1353. Epub 2018 Dec 11.
5
[Golimumab Therapy in Ulcerative Colitis].
Korean J Gastroenterol. 2016 Feb;67(2):64-73. doi: 10.4166/kjg.2016.67.2.64.
6
Golimumab for the treatment of ulcerative colitis.
Expert Opin Biol Ther. 2017 Jul;17(7):879-886. doi: 10.1080/14712598.2017.1327576. Epub 2017 May 16.
7
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
United European Gastroenterol J. 2021 Feb;9(1):102-109. doi: 10.1177/2050640620974308. Epub 2021 Mar 1.
8
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.
9
Initial experience with golimumab in clinical practice for ulcerative colitis.
Rev Esp Enferm Dig. 2016 Mar;108(3):129-32. doi: 10.17235/reed.2016.4068/2015.
10
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Dig Liver Dis. 2018 Dec;50(12):1292-1298. doi: 10.1016/j.dld.2018.06.008. Epub 2018 Jun 22.
本文引用的文献
1
Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies.
Crohns Colitis 360. 2023 Aug 26;5(3):otad044. doi: 10.1093/crocol/otad044. eCollection 2023 Jul.
2
Ulcerative colitis.
Lancet. 2023 Aug 12;402(10401):571-584. doi: 10.1016/S0140-6736(23)00966-2.
3
Classification and Management of Disorders of the J Pouch.
Am J Gastroenterol. 2023 Nov 1;118(11):1931-1939. doi: 10.14309/ajg.0000000000002348. Epub 2023 May 30.
4
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
5
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Intest Res. 2022 Apr;20(2):159-164. doi: 10.5217/ir.2021.00115. Epub 2022 Apr 29.
6
Natural history of inflammatory bowel disease: a comparison between the East and the West.
Intest Res. 2022 Oct;20(4):418-430. doi: 10.5217/ir.2021.00104. Epub 2021 Dec 2.
7
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Gastroenterology. 2022 Feb;162(2):482-494. doi: 10.1053/j.gastro.2021.10.037. Epub 2021 Oct 29.
8
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.
Dig Liver Dis. 2022 Mar;54(3):352-357. doi: 10.1016/j.dld.2021.08.020. Epub 2021 Sep 17.
9
Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance.
Intest Res. 2022 Jul;20(3):329-341. doi: 10.5217/ir.2021.00032. Epub 2021 Aug 4.
10
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
Sci Rep. 2020 Oct 20;10(1):17774. doi: 10.1038/s41598-020-73577-0.
Zotero 插件